

Munich Cancer Registry



- ▶ Incidence and Mortality
- ▶ Selection Matrix
- ▶ Homepage
- ▶ *Deutsch*

ICD-10 C61: Prostate cancer

Survival

Year of diagnosis	1988-1997	1998-2016
Patients	7,418	51,786
Diseases	7,418	51,786
Cases evaluated	6,630	42,055
Creation date	08/22/2018	
Export date	08/09/2018	
Population (males)	2.38 m	



Munich Cancer Registry
Cancer Registry Bavaria - Upper Bavaria Regional Center
at Klinikum Grosshadern/IBE
Marchioninstr. 15
Munich, 81377
Germany

<https://www.tumorregister-muenchen.de/en>

https://www.tumorregister-muenchen.de/en/facts/surv/sC61__E-ICD-10-C61-Prostate-cancer-survival.pdf

Index of figures and tables

Fig./Tbl.		Page
1a	Relative survival by period of diagnosis (chart)	3
1b	Survival by period of diagnosis (table)	3
1c	Relative survival by year of diagnosis (chart)	4
1d	Survival by year of diagnosis (table)	4
2a	Survival of total cohort (chart)	6
2b	Survival of total cohort (table)	6
3a	Observed survival by age category (chart)	7
3b	Relative survival by age category (chart)	7
3c	Survival by age category (table)	8
4a	Relative survival by TNM staging 1988+ (chart)	9
4b	Survival by TNM staging 1988+ (table)	9
4c	Relative survival by TNM staging 1998+ (chart)	11
4d	Survival by TNM staging 1998+ (table)	11
4e	Conditional survival by extent of disease (chart)	13
4f	Conditional survival by extent of disease (table)	13
5a	Time to first progression (chart)	14
5b	Time to first progression (table)	14
5c	Observed post-progression survival (chart)	16
5d	Observed post-progression survival (table)	16
5e	Observed post-progression survival by period of progression (chart)	17
5f	Observed post-progression survival by period of progression (table)	17




Figure 1a. Relative survival of patients with prostate cancer by period of diagnosis. Included in the evaluation are 47,328 cases diagnosed between 1988 and 2016.

The presented survival curves are derived from clinical records with valid follow-up informations, which means that death certificate cases (DCO) cases are omitted from the analysis. With this one restriction, the MCR has provided population-based statistics since 1998, collecting data on all cancer cases in the region of southern Bavaria. Historical data of previous time periods can be heavily selected, therefore, univariate survival comparisons of the presented time periods must be carefully considered. Nonetheless, all calculable survival curves are depicted to facilitate the comparison of long time follow-up analyses of relative survival between particular cancers.

Years	Period of diagnosis					
	1988-1997 n=6,620		1998-2006 n=18,702		2007+ n=22,006	
	obs. %	rel. %	obs. %	rel. %	obs. %	rel. %
0	100.0	100.0	100.0	100.0	100.0	100.0
1	94.5	99.2	96.0	99.4	96.1	99.1
2	88.3	97.3	91.9	98.6	92.1	98.0
3	82.4	95.4	87.8	97.5	87.8	96.5
4	77.2	93.8	84.0	96.7	84.2	95.6
5	72.4	92.3	80.3	95.9	80.5	94.7
6	68.0	91.1	76.9	95.3	77.0	93.8
7	63.6	89.5	73.2	94.3	73.6	93.1
8	59.5	88.1	69.8	93.6	70.0	92.0
9	55.9	87.0	66.4	92.8		
10	52.1	85.4	62.8	91.6		
11	48.7	84.1	59.2	90.3		
12	45.5	82.9	56.1	89.6		
13	42.1	81.0	52.9	88.7		
14	39.4	80.2	49.8	87.9		
15	37.0	79.8	47.4	88.3		

Table 1b. Observed (obs.) and relative (rel.) survival of patients with prostate cancer by period of diagnosis for period 1988-2016 (N=47,328).




Figure 1c. Relative survival of patients with prostate cancer by year of diagnosis. Included in the evaluation are 40,708 cases diagnosed between 1998 and 2016.

The survival results of the SEER program (Surveillance, Epidemiology, and End Results) of the American National Cancer Institute (NCI) are summarized as the period of diagnosis from 2000 to 2014, and are represented by colored diamonds in order to facilitate comparisons between MCR and SEER.

Years	Year of diagnosis													
	1998		1999		2000		2001		2002		2003		2004	
	obs. %	rel. %	obs. %	rel. %	obs. %	rel. %	obs. %	rel. %	obs. %	rel. %	obs. %	rel. %	obs. %	rel. %
0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0
1	92.1	96.0	95.2	99.0	96.5	100.2	94.9	98.4	96.1	99.6	96.8	100.1	97.1	100.3
2	87.6	95.1	90.5	97.8	92.3	99.4	90.9	97.8	92.2	99.1	93.2	99.7	93.4	99.5
3	82.8	93.6	85.1	95.6	88.0	98.5	86.8	96.7	88.1	98.2	89.8	99.3	89.2	98.2
4	78.4	92.3	79.4	92.8	83.9	97.6	83.3	96.4	84.2	97.2	86.4	98.9	86.2	98.2
5	73.8	90.5	75.9	92.2	79.6	96.3	79.7	95.8	81.3	97.4	82.4	97.8	82.5	97.3
6	69.7	89.1	71.9	90.9	75.8	95.4	76.9	96.0	77.1	95.9	79.1	97.3	79.2	96.8
7	65.9	87.8	68.5	90.1	72.3	94.7	73.2	95.2	73.2	94.7	75.4	96.4	76.1	96.6
8	62.6	87.1	64.7	88.5	69.0	94.2	69.2	93.8	69.4	93.4	72.1	96.0	72.8	96.0
9	58.7	85.3	61.2	87.5	65.4	93.2	65.7	92.8	65.9	92.5	68.6	95.1	69.5	95.4
10	55.0	83.6	57.3	85.5	61.6	91.9	63.1	93.1	62.6	91.7	64.6	93.6	66.3	94.9
11	51.9	82.6	54.0	84.2	58.0	90.3	59.6	92.0	59.4	91.0	60.4	91.4	62.4	93.4
12	49.2	82.1	51.3	83.6	54.1	88.3	56.8	92.1	56.6	90.9	57.2	90.6	58.7	89.0
13	46.5	81.7	48.4	82.9	50.8	87.2	52.9	90.1	53.6	90.5	54.1	89.6		
14	43.3	80.0	46.0	82.7	47.9	86.3	50.2	89.9	50.2	88.7				
15	40.5	78.9	44.1	83.7	45.9	87.2								

<i>cont'd</i>	Year of diagnosis													
	2005		2006		2007		2008		2009		2010		2011	
	n=2,639		n=2,539		n=2,979		n=2,704		n=2,474		n=2,405		n=2,576	
Years	obs. %	rel. %	obs. %	rel. %	obs. %	rel. %	obs. %	rel. %	obs. %	rel. %	obs. %	rel. %	obs. %	rel. %
0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0
1	96.5	99.7	95.6	98.7	96.4	99.4	96.2	99.2	96.0	98.9	96.1	99.0	95.9	98.9
2	92.7	99.0	91.3	97.3	93.4	99.3	92.3	98.3	91.6	97.4	91.4	97.2	91.9	97.8
3	88.9	98.1	87.4	96.3	89.5	98.2	88.2	97.0	86.8	95.1	87.7	96.4	87.8	96.6
4	84.7	96.8	83.9	95.6	85.4	96.9	85.1	96.8	82.8	93.8	83.9	95.2	84.4	96.1
5	81.3	96.2	80.2	94.7	82.2	96.5	80.9	95.2	79.4	93.0	79.6	93.5		
6	77.9	95.6	77.4	94.9	78.6	95.6	77.6	94.8	75.4	91.4				
7	74.4	94.8	73.3	93.2	75.4	95.2	74.0	93.8						
8	71.6	94.8	69.7	92.2	71.6	93.8								
9	68.4	94.5	66.5	91.6										
10	64.3	92.5												
11	60.8	91.0												

<i>cont'd</i>	Year of diagnosis									
	2012		2013		2014		2015		2016	
	n=2,658		n=2,343		n=2,344		n=1,347		n=176	
Years	obs. %	rel. %	obs. %	rel. %	obs. %	rel. %	obs. %	rel. %	obs. %	rel. %
0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0
1	96.3	99.4	95.9	98.9	96.1	99.1	95.5	97.8		
2	92.8	98.8	91.1	96.9						
3	88.1	97.0								
4	84.3	95.9								

Table 1d. Observed (obs.) and relative (rel.) survival of patients with prostate cancer by year of diagnosis for period 1998-2016 (N=40,708).




Figure 2a. Observed, expected and relative survival of the total cohort with prostate cancer. Included in the evaluation are 40,708 cases diagnosed between 1998 and 2016.

Years	Group	
	obs. %	rel. %
0	100.0	100.0
1	96.0	99.2
2	92.0	98.3
3	87.9	97.0
4	84.1	96.1
5	80.4	95.3
6	76.9	94.6
7	73.4	93.7
8	69.9	92.9
9	66.6	92.1
10	63.0	91.0
11	59.4	89.7
12	56.2	89.0
13	53.0	88.2
14	49.9	87.3
15	47.5	87.7

Table 2b. Observed (obs.) and relative (rel.) survival of the total cohort with prostate cancer for period 1998-2016 (N=40,708).




Figure 3a. Observed survival of patients with prostate cancer by age category. Included in the evaluation are 47,328 cases diagnosed between 1988 and 2016.




Figure 3b. Relative survival of patients with prostate cancer by age category. Included in the evaluation are 47,328 cases diagnosed between 1988 and 2016.

Years	Age category							
	0-59 yrs n=6,493		60-69 yrs n=18,671		70-79 yrs n=17,231		80+ yrs n=4,933	
	obs. %	rel. %	obs. %	rel. %	obs. %	rel. %	obs. %	rel. %
0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0
1	98.5	99.3	97.9	99.7	95.4	99.4	85.4	96.0
2	96.5	98.1	95.4	99.0	90.6	98.7	73.0	92.7
3	94.4	96.8	92.8	98.4	85.3	97.4	61.6	89.1
4	92.4	95.7	90.3	97.8	80.6	97.0	51.9	86.1
5	90.6	94.9	87.8	97.5	75.6	96.3	43.2	83.2
6	89.0	94.3	85.5	97.4	70.8	95.9	35.3	79.6
7	87.4	93.7	83.0	97.2	65.8	95.3	28.3	75.9
8	85.7	93.1	80.4	97.2	60.6	94.6	22.6	73.1
9	84.1	92.7	78.2	97.6	55.3	93.5	17.9	70.7
10	82.2	92.0	75.4	97.5	49.9	92.3	13.6	67.0
11	80.3	91.4	72.3	97.1	44.9	91.4	10.4	64.4
12	78.0	90.5	69.7	97.6	40.3	91.3	7.7	62.0
13	76.4	90.4	66.7	97.8	35.2	89.4	5.8	62.2
14	74.7	90.3	63.4	97.8	31.2	89.7	4.7	68.0
15	73.5	90.9	60.5	98.8	27.9	91.9	3.3	65.9

Table 3c. Observed (obs.) and relative (rel.) survival of patients with prostate cancer by age category for period 1988-2016 (N=47,328).




Figure 4a. Relative survival of patients with prostate cancer by TNM staging. For 39,064 of 47,328 cases diagnosed between 1988 and 2016 valid data could be obtained for this item. For a total of 38,986 cases an evaluable classification was established. The accumulated percentage exceeds the 100 % value because patients are potentially considered in more than one subgroup. The grey line represents the subgroup of 8,342 patients with missing values regarding TNM staging (17.6 % of 47,328 patients, the percent values of all other categories are related to n=38,986).

Years	TNM staging														
	T1		T2		T3		T4		N0		N+		NX		
	n=6,507	n=18,876	n=10,214	n=1,745	n=24,179	n=3,103	n=6,821	obs. %	rel. %	obs. %	rel. %	obs. %	rel. %	obs. %	rel. %
0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0
1	95.7	100.2	98.7	101.2	97.7	100.5	86.3	90.3	99.1	101.5	94.4	96.7	93.0	97.7	
2	91.5	100.3	97.1	102.2	94.5	100.1	72.0	78.6	97.8	102.7	87.1	91.7	86.4	95.3	
3	86.9	99.9	95.4	103.1	90.6	98.9	61.7	70.0	96.3	103.8	79.7	86.2	79.8	92.6	
4	82.3	99.4	93.5	104.0	87.0	98.0	52.5	62.2	94.5	104.7	73.1	81.3	73.9	90.2	
5	77.8	98.9	91.4	104.7	83.0	96.7	46.3	57.2	92.5	105.5	67.4	77.3	68.3	87.9	
6	73.2	98.1	89.2	105.5	79.7	96.0	40.4	52.1	90.2	106.2	63.1	74.7	63.6	86.4	
7	68.4	96.8	86.9	106.2	75.9	94.8	35.9	48.2	87.9	106.9	58.9	72.0	58.4	83.7	
8	63.0	94.5	84.5	106.9	72.5	94.0	32.5	45.6	85.6	107.8	54.5	69.0	53.5	81.1	
9	58.9	93.7	82.0	107.6	68.7	92.7	29.5	43.1	83.0	108.4	49.6	65.2	49.3	79.2	
10	53.8	91.0	79.2	108.1	64.9	91.3	25.6	39.2	79.9	108.6	45.7	62.4	44.9	76.3	

<i>cont'd</i>	TNM staging			
	M1 n=2,971		NA/NOS n=8,342	
	obs. %	rel. %	obs. %	rel. %
Years				
0	100.0	100.0	100.0	100.0
1	78.2	81.7	92.4	97.4
2	55.8	60.9	85.2	94.7
3	40.3	45.8	77.2	90.7
4	29.8	35.3	70.0	87.0
5	22.6	27.9	63.3	83.5
6	17.9	23.2	56.8	79.6
7	14.0	18.9	50.4	75.2
8	12.0	16.9	44.6	71.1
9	10.0	14.8	39.5	67.5
10	8.3	12.7	34.6	63.2

Table 4b. Observed (obs.) and relative (rel.) survival of patients with prostate cancer by TNM staging for period 1988-2016 (N=38,986).




Figure 4c. Relative survival of patients with prostate cancer by TNM staging. For 33,283 of 40,708 cases diagnosed between 1998 and 2016 valid data could be obtained for this item. For a total of 33,217 cases an evaluable classification was established. The accumulated percentage exceeds the 100 % value because patients are potentially considered in more than one subgroup. The grey line represents the subgroup of 7,491 patients with missing values regarding TNM staging (18.4 % of 40,708 patients, the percent values of all other categories are related to n=33,217).

Years	TNM staging														
	T1		T2		T3		T4		N0		N+		NX		
	n=5,529	n=17,007	n=8,135	n=1,158	n=20,876	n=2,505	n=5,233	obs. %	rel. %	obs. %	rel. %	obs. %	rel. %	obs. %	rel. %
0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0
1	95.8	99.9	98.8	101.2	98.2	100.6	87.8	91.0	99.3	101.5	94.8	97.1	94.3	98.3	
2	92.0	100.3	97.5	102.3	95.6	100.6	73.3	78.7	98.2	102.8	87.7	92.0	89.0	96.8	
3	87.6	100.0	95.7	103.1	92.3	99.7	63.9	70.9	96.9	103.9	81.1	87.3	83.4	94.7	
4	83.3	99.6	94.0	104.0	89.0	99.0	55.1	63.4	95.3	104.9	74.6	82.5	78.2	93.0	
5	79.0	99.1	91.9	104.7	85.5	98.0	48.4	57.6	93.4	105.7	69.0	78.4	73.5	91.5	
6	74.5	98.4	89.8	105.5	82.4	97.4	43.0	53.0	91.4	106.4	65.0	76.0	69.1	90.2	
7	69.7	97.1	87.7	106.3	78.8	96.3	39.3	50.2	89.3	107.3	60.7	73.2	64.2	88.0	
8	64.7	95.3	85.4	107.0	75.7	95.9	36.1	48.0	87.1	108.2	56.8	70.9	59.7	86.2	
9	60.7	94.7	83.0	107.7	72.0	94.7	33.2	45.7	84.6	108.9	52.1	67.4	55.8	84.7	
10	55.8	92.3	80.3	108.3	67.7	92.5	30.4	43.6	81.6	109.0	48.4	64.9	51.6	82.8	

<i>cont'd</i>	TNM staging			
	M1 n=2,476		NA/NOS n=7,491	
Years	obs. %	rel. %	obs. %	rel. %
0	100.0	100.0	100.0	100.0
1	78.0	81.3	92.3	97.2
2	56.9	61.5	85.0	94.3
3	41.4	46.6	77.0	90.1
4	31.3	36.6	69.9	86.4
5	24.0	29.2	63.4	83.1
6	19.3	24.5	56.7	79.0
7	15.9	20.9	50.1	74.4
8	13.4	18.5	44.1	69.8
9	11.6	16.8	38.9	65.9
10	9.8	14.7	34.3	62.0

Table 4d. Observed (obs.) and relative (rel.) survival of patients with prostate cancer by TNM staging for period 1998-2016 (N=33,217).




Figure 4e. Conditional relative 5-year survival of patients with prostate cancer by extent of disease. For 39,064 of 47,328 cases diagnosed between 1988 and 2016 valid data could be obtained for this item. For a total of 38,943 cases an evaluable classification was established. The grey line represents the subgroup of 8,385 patients with missing values regarding extent of disease (17.7 % of 47,328 patients, the percent values of all other categories are related to n=38,943).

Years	Extent of disease							
	Local		Regional		Distant		NA/NOS	
	n	Cond. surv. % 5 yrs	n	Cond. surv. % 5 yrs	n	Cond. surv. % 5 yrs	n	Cond. surv. % 5 yrs
0	33,602	103.1	2,370	89.9	2,971	27.9	8,385	83.6
1	31,307	102.5	2,167	87.7	2,158	28.5	7,302	82.6
2	29,216	101.9	1,935	86.9	1,439	31.4	6,317	80.9
3	26,896	101.7	1,685	86.1	959	37.5	5,364	80.4
4	24,457	101.6	1,451	84.7	650	43.0	4,429	80.3
5	22,080	101.2	1,245	84.3	448	46.8	3,601	79.2
6	19,902	100.9	1,072	81.4	330	49.2	2,946	78.7
7	17,634	101.1	923	81.9	232	54.4	2,422	79.0
8	15,306	101.1	753	81.6	168	49.3	1,977	78.4
9	12,905	101.0	610	84.3	126	51.4	1,602	79.7
10	10,934	102.8	511	85.3			1,277	81.2

Table 4f. Conditional relative 5-year survival of patients with prostate cancer by extent of disease for period 1988-2016 (N=38,943).

Conditional relative survival rates refer to the relative survival probability, in this case for 5 years after cancer diagnosis, compared to the age- and sex-matched population (=100 %) under the condition of being alive for a certain time period (x-axis in Figure 4c). The results illustrate to what extent the cancer induced mortality of particular subgroups declines in the subsequent years after detection of the malignancy. For instance, according to the presented survival statistics, patients in the subgroup extent of disease="Local", who are alive at least 3 years after cancer diagnosis, the conditional relative 5-year survival rate is 101.7% (n=26,896).




Figure 5a. Time to first progression of 37,900 patients with prostate cancer diagnosed between 1998 and 2016 (in solid cancers M0 only) estimated by cumulative incidence function (CI, solid line) accounting for death as competing risk and by inverse Kaplan-Meier estimate (1-KM, dashed line). The frequency of events may be underestimated due to underreporting.

Years	Type of progression						
	Any type (CI)	Any type (1-KM)	Local relapse (CI)	Local relapse (1-KM)	Lymph node (CI)	Lymph node (1-KM)	Distant metastasis (CI)
	n=37,900 %	n=37,900 %	n=37,900 %	n=37,900 %	n=37,900 %	n=37,900 %	n=37,900 %
0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
1	4.6	4.7	0.5	0.5	0.2	0.2	1.2
2	9.1	9.3	1.3	1.3	0.4	0.4	2.7
3	12.4	12.7	2.0	2.1	0.7	0.7	4.1
4	14.9	15.4	2.5	2.7	0.8	0.9	5.3
5	17.0	17.8	3.0	3.3	1.0	1.1	6.4
6	18.7	19.7	3.5	3.8	1.1	1.2	7.2
7	20.2	21.5	3.9	4.4	1.3	1.4	8.1
8	21.4	22.9	4.4	5.0	1.4	1.6	8.9
9	22.7	24.5	4.8	5.6	1.6	1.9	9.7
10	23.7	25.8	5.1	6.0	1.7	2.1	10.5
11	24.4	26.8	5.4	6.4	1.8	2.2	11.1
12	25.1	27.8	5.6	6.9	1.9	2.4	11.5
13	25.9	29.0	6.0	7.4	2.0	2.5	12.1
14	26.5	29.9	6.2	7.8	2.1	2.7	12.6
15	26.9	30.6	6.4	8.3	2.3	3.0	12.9

<i>cont'd</i>	Type of progression		
	Distant metast. (1- KM) n=37,900	NOS (CI) n=37,900	NOS (1-KM) n=37,900
Years	%	%	%
0	0.0	0.0	0.0
1	1.2	2.9	3.0
2	2.8	5.5	5.7
3	4.3	7.2	7.5
4	5.5	8.5	9.0
5	6.7	9.5	10.2
6	7.7	10.4	11.3
7	8.8	11.1	12.1
8	9.7	11.6	12.8
9	10.8	12.0	13.4
10	11.8	12.4	14.1
11	12.7	12.8	14.6
12	13.3	13.1	15.1
13	14.1	13.4	15.6
14	15.0	13.5	15.9
15	15.5	13.7	16.1

Table 5b. Time to first progression of patients with prostate cancer for period 1998-2016 (N=37,900).




Figure 5c. Observed post-progression survival of 8,441 patients with prostate cancer diagnosed between 1998 and 2016. These 8,441 patients with documented progression events during their course of disease represent 20.9 % of the totally 40,357 evaluated cases (incl. M1, n=2,457, 6.1 %). Patients with cancer relapse documented via death certificates only were excluded (n=1,487, 3.7 %). Multiple progression types on different sites are included in the evaluation even when not occurring synchronously. The NOS (not otherwise specified) class is included under the condition, that it is the one and only progression type during the course of disease.

Medical record documentation often lacks the linguistic severity to distinguish between local relapse, regional lymph node metastasis and distant spread in solid cancers. Frequently, the statement “not specified” is the only information in registries regarding relapse of the disease. The category “Any type” denotes all cases who suffered from at least one relapse during the course of disease (incl. primary M1-status). Although, the real number of relapsed patients is likely to be much higher. The accumulated percentage of patients with local relapse or distant metastasis exceeds the 100 % value because patients are potentially considered in more than one subgroup.

Years	Type of progression				
	Any type n=8,441 %	Local relapse n=1,675 %	Lymph node n=585 %	Distant metastasis n=4,360 %	NOS n=3,464 %
0	100.0	100.0	100.0	100.0	100.0
1	84.0	83.5	83.8	72.3	92.4
2	71.3	73.0	75.7	52.3	85.7
3	61.9	65.6	67.1	37.7	80.9
4	55.0	59.4	57.9	28.8	76.1
5	49.5	55.9	50.5	22.3	71.5
6	45.3	52.4	44.6	18.3	67.2
7	41.4	48.4	40.8	15.0	62.6
8	38.4	44.8	33.8	12.5	59.8
9	35.4	42.6		11.0	55.2
10	32.5	40.9		9.4	51.0

Table 5d. Observed post-progression survival of patients with prostate cancer for period 1998-2016 (N=8,441).




Figure 5e. Observed post-progression (distant metastasis) survival of 5,494 patients with prostate cancer diagnosed between 1988 and 2016 by period of progression.

Years	Period of progression		
	1988-1997 n=740 %	1988-2006 n=1,634 %	2007+ n=3,120 %
0	100.0	100.0	100.0
1	66.8	69.5	71.8
2	43.2	48.6	52.0
3	29.3	33.2	38.4
4	19.2	25.1	29.5
5	14.4	19.5	22.9
6	11.2	16.1	18.7
7	7.4	13.2	15.1
8	6.4	10.9	12.1
9	4.6	9.5	
10	3.4	8.1	

Table 5f. Observed post-progression (distant metastasis) survival of patients with prostate cancer for period 1988-2016 by period of progression (N=5,494).

Shortcuts

MCR Munich Cancer Registry, Germany

NCI National Cancer Institute, USA

SEER Surveillance, Epidemiology, and End Results, USA

UICC Union for International Cancer Control, Geneva

DCO Death certificate only Death certificate provides the only notification to the registry.

NA Not available

NOS Not otherwise specified

OS Overall/Observed survival Overall/Observed survival (Kaplan-Meier estimate)
Date of entry: diagnosis
Event: death from any cause

RS Relative survival Survival compared to “general population”,
ratio of observed to expected survival (Ederer II method),
reflecting cancer specific survival

AS Assembled survival Assembled chart of
observed, expected, relative survival

CS Conditional survival Survival probability under the condition of surviving
a given period of time

TTP Time to progression Time to first progression / relapse
Date of entry: diagnosis
Event: (progression / relapse): first local-, lymph node recurrence,
distant metastasis or unspecified progression

1-KM 1 minus Kaplan-Meier estimator
 (“inverse” Kaplan-Meier estimator)

CI Cumulative incidence
Death as competing risk (according to Kalbfleisch und Prentice)

PPS Post-progression survival Survival since first progression / relapse (Kaplan-Meier estimate)
Date of entry (progression / relapse): first local-, lymph node
recurrence, distant metastasis or unspecified progression
Event: death from any cause

Recommended Citation

Munich Cancer Registry. Survival ICD-10 C61: Prostate cancer [Internet]. 2018 [updated 2018 Aug 22; cited 2018 Oct 1]. Available from: https://www.tumorregister-muenchen.de/en/facts/surv/sC61__E-ICD-10-C61-Prostate-cancer-survival.pdf

Copyright

The content of the public web site provided by the Munich Cancer Registry is available worldwide and free of charge. All documents are free to download, utilize, copy, print-out and distribute, providing that the MCR is referenced.

Disclaimer

The Munich Cancer Registry reserves the right to not be responsible for the topicality, correctness, completeness or quality of the information provided. Liability claims regarding damage caused by the use of any information provided, including any kind of information which is incomplete or incorrect, will therefore be rejected.